Osteopore Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Osteopore şirketinin kazançları yıllık ortalama -19.3% oranında azalırken, Medical Equipment sektörünün kazançları yıllık 8.3% oranında artan oldu. Gelirler yıllık ortalama 27.4% oranında artan oldu.

Anahtar bilgiler

-19.3%

Kazanç büyüme oranı

14.8%

EPS büyüme oranı

Medical Equipment Sektör Büyümesi	5.8%
Gelir büyüme oranı	27.4%
Özkaynak getirisi	-194.7%
Net Marj	-130.2%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Osteopore nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

CHIA:OSX Gelir, gider ve kazançlar (AUD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	3	-4	4	1
31 Mar 24	2	-4	4	1
31 Dec 23	2	-5	5	2
30 Sep 23	2	-5	5	2
30 Jun 23	2	-5	5	2
31 Mar 23	2	-5	4	1
31 Dec 22	2	-4	4	1
30 Sep 22	2	-4	4	1
30 Jun 22	1	-4	4	1
31 Mar 22	1	-4	5	0
31 Dec 21	1	-4	5	0
30 Sep 21	1	-3	4	0
30 Jun 21	1	-3	4	0
31 Mar 21	1	-2	4	0
31 Dec 20	2	-2	4	0
30 Sep 20	1	-2	3	0
30 Jun 20	1	-2	3	0
31 Mar 20	1	-2	3	0
31 Dec 19	0	-2	3	0
31 Dec 18	1	-1	2	0
31 Dec 17	1	0	1	0
31 Dec 16	0	-1	1	0

Kaliteli Kazançlar: OSX şu anda kârlı değil.

Büyüyen Kar Marjı: OSX şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: OSX kârlı değildir ve zararlar son 5 yılda yılda 19.3% oranında artmıştır.

Büyüme Hızlandırma: OSX 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: OSX kârlı olmadığından, geçmiş yıl kazanç büyümesinin Medical Equipment sektörüyle ( 18.7% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: OSX hissesi şu anda kârlı olmadığından negatif Özsermaye Getirisi'ne ( -194.66% ) sahiptir.

Osteopore Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Full year 2023 earnings released: AU$0.031 loss per share (vs AU$0.51 loss in FY 2022)

First half 2023 earnings released: AU$0.019 loss per share (vs AU$0.017 loss in 1H 2022)

Full year 2022 earnings released: AU$0.034 loss per share (vs AU$0.031 loss in FY 2021)

First half 2022 earnings released: AU$0.017 loss per share (vs AU$0.012 loss in 1H 2021)

Full year 2020 earnings released: AU$0.018 loss per share (vs AU$0.083 loss in FY 2019)

Full year 2020 earnings released: AU$0.018 loss per share (vs AU$0.083 loss in FY 2019)

Recent updates

Osteopore Limited Appoints Yujing Lim as Executive Director

New major risk - Financial position

New major risk - Shareholder dilution

Less than half of directors are independent

Osteopore Limited, Annual General Meeting, May 30, 2024

Less than half of directors are independent

Osteopore Limited has filed a Follow-on Equity Offering in the amount of AUD 2.99532 million.

Full year 2023 earnings released: AU$0.031 loss per share (vs AU$0.51 loss in FY 2022)

Osteopore Limited announced that it expects to receive SGD 1 million in funding

Osteopore Limited announced that it expects to receive SGD 1 million in funding

Less than half of directors are independent

Less than half of directors are independent

Osteopore Limited Announces Resignation of Deborah Ho as Joint Company Secretary

First half 2023 earnings released: AU$0.019 loss per share (vs AU$0.017 loss in 1H 2022)

Full year 2022 earnings released: AU$0.034 loss per share (vs AU$0.031 loss in FY 2021)

Osteopore Limited Enters Orthopaedic Market in Great Britain

Osteopore Limited Announces Appointment of Kellie Davis as Joint Company Secretary, Effective 26 January 2023

Less than half of directors are independent

Osteopore Limited (ASX:OSX) agreed to acquire Businesses Of Lomic Korea, 3D Aesthetic Solutions, 3D Healthcare Solutions And 3D Aesthetic Medical Lim Jae Hoon from Lim Jae Hoon for AUD2.05 million.

Less than half of directors are independent

Less than half of directors are independent

First half 2022 earnings released: AU$0.017 loss per share (vs AU$0.012 loss in 1H 2021)

Insider recently bought AU$1.9m worth of stock

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Osteopore Limited Announces Appointment of Dr. Lim Jing as Chief Operating Officer

Osteopore Limited, Annual General Meeting, May 31, 2022

Less than half of directors are independent

Osteopore Limited Announces Resignation of Vlado Bosanac as Non-Executive Director

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Less than half of directors are independent

Non Executive Chairman Brett Sandercock has left the company

Full year 2020 earnings released: AU$0.018 loss per share (vs AU$0.083 loss in FY 2019)

Full year 2020 earnings released: AU$0.018 loss per share (vs AU$0.083 loss in FY 2019)

Osteopore Limited Announces A Cooperation Agreement with Terumo Blood and Cell Technologies

Osteopore International Collaborates with Maastricht University Medical Centre to Develop Implant Solution That Prevents Leg Amputations

Osteopore Limited Signs Distribution Agreement with MTG Medizintechnik Göhl

Osteopore Limited Announce the Appointment of Carl Runde as Chief Financial Officer

First half earnings released

Osteopore Limited has completed a Follow-on Equity Offering in the amount of AUD 8.5 million.

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin